Previous 10 | Next 10 |
Merus (MRUS): Q3 GAAP EPS of -$0.64 misses by $0.07.Revenue of $8.57M (+5.0% Y/Y) beats by $1.12M.Cash, cash equivalents and marketable securities of $190.2M.Press Release For further details see: Merus EPS misses by $0.07, beats on revenue
– Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021 – – MCLA-129 expected to enter clinic in 2021 – UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Merus N...
Merus (MRUS) and myTomorrows, a global health technology company have expanded their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers. Under a 2019 agreement, myTomorrows has been successfully prov...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonic...
Youdao (DAO), Avrobio (AVRO), Merus (MRUS), and PrimeEnergy (PNRG) are four stocks recently downgraded by the POWR Ratings. If the market decline resumes, it's likely that these stocks will lead to the downside. The latest POWR Ratings have arrived. A wide array of stocks w...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg...
Merus (NASDAQ: MRUS ) : Q2 GAAP EPS of -$0.54 beats by $0.12 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 – UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: M...
The FDA has designated Orphan Drug status for Merus's ( MRUS -0.9% ) Zenocutuzumab (Zeno) for the treatment of pancreatic cancer. More news on: Merus N.V., Healthcare stocks news, Read more ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the appointment of Andrew J...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...